Purpose: The prognostic significance of pretreatment serum C-terminus of cytokeratin 19 (CYFRA21-1, CYFRA) status was evaluated in the patients with surgically treated esophageal squamous cell carcinoma.
Methods: A total of 1047 patients with surgically treated esophageal cancer were enrolled in a multi-institutional study promoted by the Japanese Esophageal Society. This study included an up-front surgery group (n = 412), a neoadjuvant chemotherapy (NAC) group (n = 486), and a neoadjuvant chemoradiation/radiation therapy (NACRT/RT) group (n = 149). The pretreatment CYFRA status was analyzed to assess prognostic significance using multivariate analysis according to treatment modalities.
Results: The CYFRA-positive group was significantly associated with deep tumor. Univariate analysis showed that the overall survival of the CYFRA-positive group was significantly worse than that of the CYFRA-negative group, but the difference was not significant in the multivariate analysis. CYFRA was an independent risk factor for poor prognosis just in the NACRT/RT group.
Conclusions: The CYFRA-positive group was associated with deep tumor and poor survival. Pretreatment CYFRA was not an independent risk factor for poor prognosis in the up-front surgery group or NAC group. It was an independent risk factor for poor prognosis just in the NACRT/RT group.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9209890 | PMC |
| http://dx.doi.org/10.5761/atcs.oa.21-00195 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Assessing the 9G Technology Blood Test for Predicting Lung Cancer in Patients with CT-Detected Lung Nodules: A Multicenter Clinical Trial.
Cancers (Basel)
November 2024
Precision Medicine Lung Cancer Center, Konkuk University Medical Center, Seoul 05029, Republic of Korea.
: Lung nodules detected by chest computed tomography (CT) often require invasive biopsies for definitive diagnosis, leading to unnecessary procedures for benign lesions. A blood-based biomarker test that predicts lung cancer risk in CT-detected nodules could help stratify patients and direct invasive diagnostics toward high-risk individuals. : In this multicenter, single-blinded clinical trial, we evaluated a test measuring plasma levels of p53, anti-p53 autoantibodies, CYFRA 21-1, and anti-CYFRA 21-1 autoantibodies in patients with CT-detected lung nodules.
View Article and Find Full Text PDFSerum CYFRA 21-1 as a Prognostic Marker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Cancers (Basel)
November 2024
Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo 135-8550, Japan.
Article Synopsis
- This study investigates the use of serum cytokeratin fraction 21-1 (CYFRA 21-1) as a prognostic marker for patients with non-small-cell lung cancer (NSCLC) treated with anti-PD-1/PD-L1 antibodies, focusing on different histologies and treatments.* -
- A total of 258 patients without driver mutations were evaluated, revealing that squamous NSCLC patients had shorter overall survival compared to non-squamous patients, particularly those with elevated CYFRA 21-1 and carcinoembryonic antigen (CEA) levels.* -
- The study found that high levels of CYFRA 21-1 indicated poor prognosis across various treatments, establishing it
Retrospective evaluation of plasma protein tumour markers for early lung cancer detection.
BJC Rep
August 2024
Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular & Integrative Biology, The University of Liverpool, Liverpool, UK.
Background: Blood-based biomarkers might help lung cancer diagnosis. A panel of serum tumour markers (TM) has been validated for hospital referrals due to clinical suspicion of lung cancer. We have compared plasma from a cohort enriched for early-stage lung cancer, including controls from a healthy population cohort.
View Article and Find Full Text PDFBackground: This study aimed to establish reference intervals for two biomarkers actively utilized in routine annual medical check-ups in China: squamous cell carcinoma antigen (SCCA) and cytokeratin 19 fragment (CYRFA 21-1), and to understand the influence of age, gender, and benign nodule(s) on their levels.
Methods: This prospective multicenter cross-sectional study continuously enrolled apparently healthy adults attending annual medical check-ups at three sites in 2019. Serum SCCA and CYFRA 21-1 levels were measured using electrochemiluminescence immunoassays.
Serum cyfra21-1 is a new prognostic biomarker of penile squamous cell carcinoma.
BMC Cancer
October 2024
Department of Urinary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, 510060, P. R. China.
Article Synopsis
- The study aimed to assess the prognostic value of preoperative serum cyfra21-1 levels in patients with penile squamous cell carcinoma (PSCC), analyzing data from 94 patients over an average follow-up of 66.5 months.
- Results showed that 27.6% of patients had elevated cyfra21-1 levels, which were associated with higher rates of disease relapse and death compared to those with normal levels.
- The findings indicate that elevated cyfra21-1 levels, along with lymph node involvement and ECOG performance status, are significant independent predictors of worse disease-free and disease-specific survival in PSCC patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!